Visionary Education stock soars after strategic biotech partnership

Published 17/09/2025, 16:34
© Reuters.

Investing.com -- Visionary Education Technology Holdings Group Inc (NASDAQ:GV) stock surged 76.4% Wednesday after the company announced a strategic partnership with Jiangsu Yike Regenerative Medicine, a leading Chinese regenerative medical research institute.

The technology-driven multinational enterprise will collaborate with Yike on research, development, and commercialization in cellular rejuvenation and aesthetic treatment. This partnership marks GV’s strategic entry into the Consumption Healthcare sector, specifically targeting the Medical Aesthetics industry.

Under the agreement, Yike will lead and fund the research and development efforts, while GV may later acquire or license the intellectual property rights through cash or share-based transactions. The partnership will focus on cell activation and telomerase homeostasis, smart delivery systems with personalized solutions, and stem cell applications.

The collaboration will leverage Yike’s proprietary technologies, including its Cell-Activating Complex, Nano-Delivery ultra-permeable liposomal technology, and AI-based Aging Assessment Model. GV will work closely with Dr. Zhenyu Ju, Yike’s Chief Scientist and Dean of the Institute of Aging and Regenerative Medicine at Jinan University.

Dr. Ju, a recipient of China’s National Science Fund for Distinguished Young Scholars, stated: "We are very pleased to collaborate with GV, a company with strong international marking experience and global vision. GV’s global resources and commercialization experience are highly complementary to Yike’s research into aging interventions. This partnership will accelerate the translation of fundamental research into clinical applications, delivering safer and more effective anti-aging solutions to consumers in China and worldwide."

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.